Literature DB >> 30345412

Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer.

Chun-Chin Chen1,2, Weiran Feng1,3, Pei Xin Lim1, Elizabeth M Kass1, Maria Jasin1,2,3.   

Abstract

Germ-line and somatic mutations in genes that promote homology-directed repair (HDR), especially BRCA1 and BRCA2, are frequently observed in several cancers, in particular, breast and ovary but also prostate and other cancers. HDR is critical for the error-free repair of DNA double-strand breaks and other lesions, and HDR factors also protect stalled replication forks. As a result, loss of BRCA1 or BRCA2 poses significant risks to genome integrity, leading not only to cancer predisposition but also to sensitivity to DNA-damaging agents, affecting therapeutic approaches. Here we review recent advances in our understanding of BRCA1 and BRCA2, including how they genetically interact with other repair factors, how they protect stalled replication forks, how they affect the response to aldehydes, and how loss of their functions links to mutation signatures. Importantly, given the recent advances with poly(ADP-ribose) polymerase inhibitors (PARPi) for the treatment of HDR-deficient tumors, we discuss mechanisms by which BRCA-deficient tumors acquire resistance to PARPi and other agents.

Entities:  

Keywords:  ATM; BRCA1; BRCA2; double-strand break repair; homologous recombination; replication fork protection

Year:  2017        PMID: 30345412      PMCID: PMC6193498          DOI: 10.1146/annurev-cancerbio-030617-050502

Source DB:  PubMed          Journal:  Annu Rev Cancer Biol        ISSN: 2472-3428


  206 in total

1.  BRCA2 fine-tunes the spindle assembly checkpoint through reinforcement of BubR1 acetylation.

Authors:  Eunhee Choi; Pil-Gu Park; Hae-Ock Lee; Yoo-Kyung Lee; Gyeong Hoon Kang; Jong Won Lee; Wonshik Han; Ho Chang Lee; Dong-Young Noh; Sergey Lekomtsev; Hyunsook Lee
Journal:  Dev Cell       Date:  2012-02-14       Impact factor: 12.270

2.  Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks.

Authors:  D Cortez; Y Wang; J Qin; S J Elledge
Journal:  Science       Date:  1999-11-05       Impact factor: 47.728

Review 3.  Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application.

Authors:  Vindhya Koppaka; David C Thompson; Ying Chen; Manuel Ellermann; Kyriacos C Nicolaou; Risto O Juvonen; Dennis Petersen; Richard A Deitrich; Thomas D Hurley; Vasilis Vasiliou
Journal:  Pharmacol Rev       Date:  2012-04-27       Impact factor: 25.468

4.  ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.

Authors:  Chris T Williamson; Huong Muzik; Ali G Turhan; Alberto Zamò; Mark J O'Connor; D Gwyn Bebb; Susan P Lees-Miller
Journal:  Mol Cancer Ther       Date:  2010-02-02       Impact factor: 6.261

5.  The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression.

Authors:  Reena Shakya; Matthias Szabolcs; Ellen McCarthy; Elson Ospina; Katia Basso; Subhadra Nandula; Vundavalli Murty; Richard Baer; Thomas Ludwig
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-28       Impact factor: 11.205

6.  Relationship between DNA damage and survival in formaldehyde-treated mouse cells.

Authors:  W E Ross; N Shipley
Journal:  Mutat Res       Date:  1980-11       Impact factor: 2.433

7.  REV7 counteracts DNA double-strand break resection and affects PARP inhibition.

Authors:  J Ross Chapman; Inger Brandsma; Guotai Xu; Jingsong Yuan; Martin Mistrik; Peter Bouwman; Jirina Bartkova; Ewa Gogola; Daniël Warmerdam; Marco Barazas; Janneke E Jaspers; Kenji Watanabe; Mark Pieterse; Ariena Kersbergen; Wendy Sol; Patrick H N Celie; Philip C Schouten; Bram van den Broek; Ahmed Salman; Marja Nieuwland; Iris de Rink; Jorma de Ronde; Kees Jalink; Simon J Boulton; Junjie Chen; Dik C van Gent; Jiri Bartek; Jos Jonkers; Piet Borst; Sven Rottenberg
Journal:  Nature       Date:  2015-03-23       Impact factor: 49.962

8.  BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.

Authors:  Rinske Drost; Peter Bouwman; Sven Rottenberg; Ute Boon; Eva Schut; Sjoerd Klarenbeek; Christiaan Klijn; Ingrid van der Heijden; Hanneke van der Gulden; Ellen Wientjens; Mark Pieterse; Aurelie Catteau; Pete Green; Ellen Solomon; Joanna R Morris; Jos Jonkers
Journal:  Cancer Cell       Date:  2011-12-13       Impact factor: 31.743

9.  BRCA1 haploinsufficiency for replication stress suppression in primary cells.

Authors:  Shailja Pathania; Sangeeta Bade; Morwenna Le Guillou; Karly Burke; Rachel Reed; Christian Bowman-Colin; Ying Su; David T Ting; Kornelia Polyak; Andrea L Richardson; Jean Feunteun; Judy E Garber; David M Livingston
Journal:  Nat Commun       Date:  2014-11-17       Impact factor: 14.919

10.  53BP1 is a reader of the DNA-damage-induced H2A Lys 15 ubiquitin mark.

Authors:  Amélie Fradet-Turcotte; Marella D Canny; Cristina Escribano-Díaz; Alexandre Orthwein; Charles C Y Leung; Hao Huang; Marie-Claude Landry; Julianne Kitevski-LeBlanc; Sylvie M Noordermeer; Frank Sicheri; Daniel Durocher
Journal:  Nature       Date:  2013-06-12       Impact factor: 49.962

View more
  89 in total

1.  Inadequate DNA Damage Repair Promotes Mammary Transdifferentiation, Leading to BRCA1 Breast Cancer.

Authors:  Hua Wang; Dongxi Xiang; Ben Liu; Aina He; Helena J Randle; Kelvin Xi Zhang; Anushka Dongre; Norman Sachs; Allison P Clark; Luwei Tao; Qing Chen; Vladimir V Botchkarev; Ying Xie; Ning Dai; Hans Clevers; Zhe Li; David M Livingston
Journal:  Cell       Date:  2019-06-27       Impact factor: 41.582

Review 2.  BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis.

Authors:  John J Krais; Neil Johnson
Journal:  Cancer Res       Date:  2020-08-03       Impact factor: 12.701

3.  Thirdhand smoke exposure causes replication stress and impaired transcription in human lung cells.

Authors:  Altaf H Sarker; Kelly S Trego; Weiguo Zhang; Peyton Jacob; Antoine M Snijders; Jian-Hua Mao; Suzaynn F Schick; Priscilla K Cooper; Bo Hang
Journal:  Environ Mol Mutagen       Date:  2020-04-16       Impact factor: 3.216

Review 4.  Inflammation-induced DNA damage, mutations and cancer.

Authors:  Jennifer Kay; Elina Thadhani; Leona Samson; Bevin Engelward
Journal:  DNA Repair (Amst)       Date:  2019-07-25

Review 5.  The origin of human mutation in light of genomic data.

Authors:  Vladimir B Seplyarskiy; Shamil Sunyaev
Journal:  Nat Rev Genet       Date:  2021-06-23       Impact factor: 53.242

Review 6.  ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications.

Authors:  Samantha A Armstrong; Christopher W Schultz; Ariana Azimi-Sadjadi; Jonathan R Brody; Michael J Pishvaian
Journal:  Mol Cancer Ther       Date:  2019-11       Impact factor: 6.261

7.  53BP1 Enforces Distinct Pre- and Post-resection Blocks on Homologous Recombination.

Authors:  Elsa Callen; Dali Zong; Wei Wu; Nancy Wong; Andre Stanlie; Momoko Ishikawa; Raphael Pavani; Lavinia C Dumitrache; Andrea K Byrum; Carlos Mendez-Dorantes; Paula Martinez; Andres Canela; Yaakov Maman; Amanda Day; Michael J Kruhlak; Maria A Blasco; Jeremy M Stark; Nima Mosammaparast; Peter J McKinnon; André Nussenzweig
Journal:  Mol Cell       Date:  2019-10-22       Impact factor: 17.970

8.  RNF168-Mediated Ubiquitin Signaling Inhibits the Viability of BRCA1-Null Cancers.

Authors:  John J Krais; Yifan Wang; Andrea J Bernhardy; Emma Clausen; Jessica A Miller; Kathy Q Cai; Clare L Scott; Neil Johnson
Journal:  Cancer Res       Date:  2020-03-25       Impact factor: 12.701

Review 9.  The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.

Authors:  Madalena Tarsounas; Patrick Sung
Journal:  Nat Rev Mol Cell Biol       Date:  2020-02-24       Impact factor: 94.444

Review 10.  Understanding and overcoming resistance to PARP inhibitors in cancer therapy.

Authors:  Mariana Paes Dias; Sarah C Moser; Shridar Ganesan; Jos Jonkers
Journal:  Nat Rev Clin Oncol       Date:  2021-07-20       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.